From: Clinical features and treatment efficacy for IgG4-related thyroiditis
Parameters | IgG4-related thyroiditis (n = 14) | IgG4-RD without thyroiditis (n = 42) | P value |
---|---|---|---|
HgB (g/L) | 138 ± 9 | 135 ± 14 | 0.293 |
WBC (109/L) | 6.77 ± 2.28 | 6.64 ± 1.59 | 0.843 |
PLT (109/L) | 265 ± 55 | 215 ± 66 | 0.013* |
Eos% (%) | 3.8 ± 6.0 | 4.8 ± 5.6 | 0.564 |
ESR (mm/h), M (Q1–Q3) | 27 (14–36) | 31 (7–56) | 0.532 |
hsCRP (mg/L), M (Q1–Q3) | 2.06 (0.33–3.99) | 5.38 (0.41–5.08) | 0.309 |
IgG (g/L) | 23.56 ± 8.14 | 23.17 ± 14.22 | 0.924 |
IgA (g/L) | 2.52 ± 1.01 | 2.18 ± 1.53 | 0.495 |
IgM (g/L) | 1.16 ± 0.51 | 0.99 ± 1.09 | 0.616 |
IgG1 (mg/L), M (Q1–Q3) | 12,414 (7730–15,300) | 10,204 (7745–11,100) | 0.149 |
IgG2 (mg/L), M (Q1–Q3) | 6497 (3850–7870) | 7039 (4235–8020) | 0.782 |
IgG3 (mg/L), M (Q1–Q3) | 413 (139–573) | 732 (314–1105) | 0.050* |
IgG4 (mg/L), M (Q1–Q3) | 4750 (2503–8505) | 18,765 (2055–25,275) | 0.004* |
T-IgE (KU/L), M ( Q1–Q3) | 100.3 (16.4–175.0) | 474.3 (60.4–564.3) | 0.006* |
Decline of C3 (n, %) | 1 (7.1) | 6 (14.3) | 0.666 |
Decline of C4 (n, %) | 1 (7.1) | 7 (16.7) | 0.664 |